BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30613284)

  • 1. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
    Werner RA; Weich A; Kircher M; Solnes LB; Javadi MS; Higuchi T; Buck AK; Pomper MG; Rowe SP; Lapa C
    Theranostics; 2018; 8(22):6088-6100. PubMed ID: 30613284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy.
    Pencharz D; Gnanasegaran G; Navalkissoor S
    Br J Radiol; 2018 Nov; 91(1091):20180108. PubMed ID: 30102557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT.
    Werner RA; Thackeray JT; Pomper MG; Bengel FM; Gorin MA; Derlin T; Rowe SP
    J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31331016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostic in Nuclear Medicine - The paradigm of NET.
    Giammarile F
    Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide Receptor Radionuclide Therapy with
    Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
    J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
    Kulkarni HR; Baum RP
    PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.
    Park S; Parihar AS; Bodei L; Hope TA; Mallak N; Millo C; Prasad K; Wilson D; Zukotynski K; Mittra E
    J Nucl Med; 2021 Oct; 62(10):1323-1329. PubMed ID: 34301785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors].
    Werner RA; Bengel FM; Derlin T
    Radiologe; 2020 May; 60(5):413-420. PubMed ID: 32052116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
    Werner RA; Ilhan H; Lehner S; Papp L; Zsótér N; Schatka I; Muegge DO; Javadi MS; Higuchi T; Buck AK; Bartenstein P; Bengel F; Essler M; Lapa C; Bundschuh RA
    Mol Imaging Biol; 2019 Jun; 21(3):582-590. PubMed ID: 30014345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.
    Fortunati E; Argalia G; Zanoni L; Fanti S; Ambrosini V
    Curr Treat Options Oncol; 2022 May; 23(5):703-720. PubMed ID: 35325412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).
    Kong G; Grozinsky-Glasberg S; Hofman MS; Akhurst T; Meirovitz A; Maimon O; Krausz Y; Godefroy J; Michael M; Gross DJ; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):718-727. PubMed ID: 30343432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.
    Werner RA; Lapa C; Ilhan H; Higuchi T; Buck AK; Lehner S; Bartenstein P; Bengel F; Schatka I; Muegge DO; Papp L; Zsótér N; Große-Ophoff T; Essler M; Bundschuh RA
    Oncotarget; 2017 Jan; 8(4):7039-7049. PubMed ID: 27705948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.
    Vija L; Dierickx L; Courbon F
    Ann Endocrinol (Paris); 2019 Jun; 80(3):166-171. PubMed ID: 31053248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.
    Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Higuchi T; Weich A; Sheikhbahaei S; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
    Ann Nucl Med; 2018 Oct; 32(8):512-522. PubMed ID: 30109562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework.
    Werner RA; Solnes LB; Javadi MS; Weich A; Gorin MA; Pienta KJ; Higuchi T; Buck AK; Pomper MG; Rowe SP; Lapa C
    J Nucl Med; 2018 Jul; 59(7):1085-1091. PubMed ID: 29572257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
    Haug AR; Auernhammer CJ; Wängler B; Schmidt GP; Uebleis C; Göke B; Cumming P; Bartenstein P; Tiling R; Hacker M
    J Nucl Med; 2010 Sep; 51(9):1349-56. PubMed ID: 20720050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.